Real-world outcomes for multiple myeloma patients after apheresis for planned chimeric antigen receptor T-cell therapy

doi:10.5493/wjem.125753

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 3

This Article

(1)

(0)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Experimental Medicine

ISSN

2220-315x

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Exp Med. Sep 20, 2026; 16(3): 125753
Published online Sep 20, 2026. doi: 10.5493/wjem.125753

Table 4 Kaplan-Meier estimates and numbers at risk from the date of apheresis

Months from apheresis	0	3	6	12	18	24	30
PFS - infused: At risk	87	82	65	37	16	6	1
PFS - infused: % (95%CI)	100	94.3 (86.7-97.6)	81.0 (71.2-87.6)	67.9 (56.9-76.8)	49.2 (37.5-60.0)	32.6 (21.1-44.6)	20.9 (9.6-35.2)
PFS - not infused: At risk	12	2	1	0	0	0	0
PFS - not infused: % (95%CI)	100	16.7 (2.7-41.3)	8.3 (0.5-31.1)	0	0	0	0
OS - infused: At risk	87	85	76	50	27	15	6
OS - infused: % (95%CI)	100	97.7 (91.1-99.4)	94.1 (86.6-97.4)	88.6 (79.6-93.8)	82.7 (72.2-89.5)	75.1 (62.6-84.0)	65.7 (48.3-78.5)
OS - not infused: At risk	12	3	2	0	0	0	0
OS - not infused: % (95%CI)	100	25.0 (6.0-50.5)	20.0 (3.5-46.0)	10.0 (0.6-35.8)	0	0	0

Median progression-free survival: Infused 17.5 months [95% confidence interval (CI): 12.7-21.6); not infused 1.5 months (95%CI 0.8-2.3)]; log-rank P < 0.001. Median overall survival: Infused not reached (95%CI not estimable); not infused 1.9 months (95%CI 1.0-6.2); log-rank P < 0.001. Where the survival function equalled exactly 0.50 across an interval, the median is reported as the interval midpoint. CI: Confidence interval; OS: Overall survival; PFS: Progression-free survival.

Full Size Table

Citation: Bangolo A, Gill S, Zhang L, Zhao J, Amoozgar B, Reich-Slotky R, Tran J, Vo T, Mariblanca G, Balulescu X, Mcknight S, Patel N, Reed A, Kaur S, Subramanian S, Katyal J, Manikkuttiyil C, Chakov M, Nguyen A, Pashine S, Khalil A, Mathew S, Gill R, Andrews V, Ordonez P, Olson B, Koleng M, Persaud R, Saride HS, Dharsi M, Thach R, Chen W, Shahid M, Weissman S, Siegel D, Parmar H, Biran N, Vesole DH, Phull P. Real-world outcomes for multiple myeloma patients after apheresis for planned chimeric antigen receptor T-cell therapy. World J Exp Med 2026; 16(3): 125753
URL: https://www.wjgnet.com/2220-315x/full/v16/i3/125753.htm
DOI: https://dx.doi.org/10.5493/wjem.125753

Bangolo A, Gill S, Zhang L, Zhao J, Amoozgar B, Reich-Slotky R, Tran J, Vo T, Mariblanca G, Balulescu X, Mcknight S, Patel N, Reed A, Kaur S, Subramanian S, Katyal J, Manikkuttiyil C, Chakov M, Nguyen A, Pashine S, Khalil A, Mathew S, Gill R, Andrews V, Ordonez P, Olson B, Koleng M, Persaud R, Saride HS, Dharsi M, Thach R, Chen W, Shahid M, Weissman S, Siegel D, Parmar H, Biran N, Vesole DH, Phull P. Real-world outcomes for multiple myeloma patients after apheresis for planned chimeric antigen receptor T-cell therapy. World J Exp Med 2026; 16(3): 125753 [DOI: 10.5493/wjem.125753]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.